References
- 1. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003; 228: 1-14.
- 2. Dusso A, González EA, Martin KJ. Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab. 2011; 25: 647-55.
- 3. Iglesias P, Carrero JJ, Díez JJ. Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J Nephrol. 2012; 25: 31-42.
- 4. Ros S, Carrero JJ. Endocrine alterations and cardiovascular risk in CKD: Is there a link? Nefrologia. 2013; 33: 181-87.
- 5. Carrero JJ, Stenvinkel P. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transplant. 2012; 27: 4030-41.
- 6. Holley JL. The hypothalamic-pituitary axis in men and women with chronic kidney disease. Adv Chronic Kidney Dis. 2004; 11: 337-41.
- 7. Sugiya N, Nakashima A, Takasugi N, et al. Endogenous estrogen may prevent bone loss in postmenopausal hemodialysis patients throughout life. Osteoporos Int. 2011; 22: 1573-9.
- 8. Mak RH, Cheung WW, Roberts CT Jr. The growth hormone-insulin-like growth factor-I axis in chronic kidney disease. Growth Horm IGF Res. 2008; 18: 17-25.
- 9. Gupta D, Gardner M, Whaley-Connell A. Role of growth hormone deficiency and treatment in chronic kidney disease. Cardiorenal Med. 2011; 1: 174-82.
- 10. Wiezel D, Assadi MH, Landau D, Troib A, Kachko L, Rabkin R, Segev Y. Impaired renal growth hormone JAK/STAT5 signaling in chronic kidney disease. Nephrol Dial Transplant. 2014; 29: 791-9.
- 11. Mahesh S, Kaskel F. Growth hormone axis in chronic kidney disease. Pediatr Nephrol. 2008; 23: 41-8.
- 12. Salas P, Pinto V, Rodriguez J, Zambrano MJ, Mericq V. Growth retardation in children with kidney disease. Int J Endocrinol. 2013; doi: 10.1155/2013/970946
- 13. Haffner D, Schaefer F, Nissel R, Wühl E, Tönshoff B, Mehls O. Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. N Engl J Med. 2000; 343: 923-30.
- 14. Mehls O, Lindberg A, Nissel R, Haffner D, Hokken- Koelega A, Ranke MB. Predicting the response to growth hormone treatment in short children with chronic kidney disease. J Clin Endocrinol Metab. 2010; 95: 686-92
- 15. Iglesias P, Díez JJ. Thyroid dysfunction and kidney disease. Eur J Endocrinol. 2009; 160: 503-15.
- 16. Abdel-Rahman EM, Mansour W, Holley JL. Thyroid hormone abnormalities and frailty in elderly patients with chronic kidney disease: a hypothesis. Semin Dial. 2010; 23: 317-23.
- 17. Basu G, Mohapatra A. Interactions between thyroid disorders and kidney disease. Indian J Endocrinol Metab. 2012; 16: 204-13.
- 18. Mohamedali M, Reddy Maddika S, Vyas A, Iyer V, Cheriyath P. Thyroid disorders and chronic kidney disease. Int J Nephrol. 2014; doi: 10.1155/2014/520281.
- 19. Xu G, Yan W, Li J. An update for the controversies and hypotheses of regulating nonthyroidal illness syndrome in chronic kidney diseases. Clin Exp Nephrol. 2014; 18: 837-43.
- 20. Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P. Low triiodothyronine and survival in endstage renal disease. Kidney Int. 2006; 70: 523-8
- 21. Lu Y, Ku E, Campese VM, Aldosterone in the pathogenesis of chronic kidney disease and proteinuria. Curr Hypertens Rep. 2010; 12: 303-6.
- 22. Liao MT, Sung CC, Hung KC, Wu CC, Lo L, Lu KC. Insulin resistance in patients with chronic kidney disease. J Biomed Biotechnol. 2012; 2012: 691369.
- 23. Siew ED, Ikizler TA. Insulin resistance and protein energy metabolism in patients with advanced chronic kidney disease. Semin Dial. 2010; 23: 378-82.
- 24. Adamczak M, Wiecek A. The adipose tissue as an endocrine organ. Semin Nephrol. 2013; 33: 2-13.